Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Abstract

ClinicalTrials.gov NCT02151981; https://clinicaltrials.gov/ct2/show/NCT02151981.